{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:01:47Z","timestamp":1776805307776,"version":"3.51.2"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ncl.2025.12.002","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:12:46Z","timestamp":1768824766000},"page":"321-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates on Treatment in Thyroid Eye Disease for the Neurologist"],"prefix":"10.1016","volume":"44","author":[{"given":"Saif Aldeen","family":"Alryalat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Acil","family":"Alasheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qusai Abu","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisrein","family":"Yaaqba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib1","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid Association and the European thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ncl.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1210\/jc.2002-030010","article-title":"Pathophysiology of graves\u2019 ophthalmopathy: the cycle of disease","volume":"88","author":"Bahn","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jcem-44-1-203","article-title":"Modification of the classification of the eye changes of graves\u2019 disease: recommendations of the Ad Hoc Committee of the American thyroid Association","volume":"44","author":"Werner","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.002_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.1991.1.357","article-title":"Classification of the eye changes of graves\u2019 disease","volume":"1","author":"Wiersinga","year":"1991","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.002_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/thy.1998.8.539","article-title":"The measurement of change in graves\u2019 ophthalmopathy","volume":"8","author":"Gorman","year":"1998","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","article-title":"Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment","volume":"55","author":"Dickinson","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.002_bib9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0002-9394(14)72787-4","article-title":"Diagnostic criteria for graves\u2019 ophthalmopathy","volume":"119","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of graves\u2019 ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ncl.2025.12.002_bib12","series-title":"Recent developments in graves\u2019 ophthalmopathy","first-page":"115","article-title":"Radiotherapy for Graves\u2019 ophthalmopathy","author":"Kahaly","year":"2000"},{"issue":"11","key":"10.1016\/j.ncl.2025.12.002_bib13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.35.11.1628","article-title":"Dysthyroid orbitopathy","volume":"35","author":"Dresner","year":"1985","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"10.1016\/j.ncl.2025.12.002_bib16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth Factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","article-title":"Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease","volume":"107","author":"Krieger","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40618-020-01361-y","article-title":"Dysthyroid optic neuropathy: evaluation and management","volume":"44","author":"Dolman","year":"2021","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/105072502753600205","article-title":"Psychosocial factors in subjects with thyroid-associated ophthalmopathy","volume":"12","author":"Kahaly","year":"2002","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03345275","article-title":"Effects of Graves\u2019 ophthalmopathy on quality of life","volume":"27","author":"Wiersinga","year":"2004","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/jc.2012-3119","article-title":"Public health relevance of graves\u2019 orbitopathy","volume":"98","author":"Ponto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.002_bib24","first-page":"168","article-title":"Management of graves\u2019 ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves\u2019 disease","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption","volume":"45","author":"Pfeilschifter","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy","volume":"87","author":"Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of graves\u2019 ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ncl.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for graves\u2019 hyperthyroidism","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ncl.2025.12.002_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0002-9394(84)90127-2","article-title":"Determination of the normal range of exophthalmometric values for Black and white adults","volume":"98","author":"Migliori","year":"1984","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ncl.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy","volume":"24","author":"Curr\u00f2","year":"2014","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","article-title":"Acute thyroid eye disease (TED): principles of medical and surgical management","volume":"27","author":"Verity","year":"2013","journal-title":"Eye"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.002_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/WNO.0000000000000128","article-title":"Thyroid eye disease","volume":"34","author":"Bhatti","year":"2014","journal-title":"J Neuro Ophthalmol"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.002_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa140","article-title":"Trends in treatment of active, moderate-to-severe thyroid eye disease in the United States","volume":"4","author":"Wang","year":"2020","journal-title":"J Endocr Soc"},{"issue":"Supplement_1","key":"10.1016\/j.ncl.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imj.15067","article-title":"Medical and surgical treatment of thyroid eye disease","volume":"52","author":"Hall","year":"2022","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.002_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IIO.0000000000000357","article-title":"Glucocorticoids for thyroid eye disease","volume":"61","author":"Dolman","year":"2021","journal-title":"Int Ophthalmol Clin"},{"issue":"7","key":"10.1016\/j.ncl.2025.12.002_bib39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-9071.2010.02332.x","article-title":"Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy","volume":"38","author":"Alkawas","year":"2010","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ncl.2025.12.002_bib40","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3341\/kjo.2024-0031","article-title":"A review of novel medical treatments for thyroid eye disease","volume":"38","author":"Park","year":"2024","journal-title":"Kor J Ophthalmol"},{"issue":"20","key":"10.1016\/j.ncl.2025.12.002_bib42","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe graves\u2019 ophthalmopathy","volume":"321","author":"Prummel","year":"1989","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ncl.2025.12.002_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v . prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.ncl.2025.12.002_bib44","article-title":"Rituximab for thyroid-associated ophthalmopathy","volume":"2022","author":"Kang","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ncl.2025.12.002_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ncl.2025.12.002_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ncl.2025.12.002_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medcli.2022.05.007","article-title":"Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease","volume":"160","author":"Pamp\u00edn-S\u00e1nchez","year":"2023","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"12","key":"10.1016\/j.ncl.2025.12.002_bib50","first-page":"CD007630","article-title":"Surgical orbital decompression for thyroid eye disease","author":"Boboridis","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ncl.2025.12.002_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/249125","article-title":"Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management","volume":"2015","author":"Barrio-Barrio","year":"2015","journal-title":"J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ncl.2025.12.002_bib52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/thy.2008.0033","article-title":"Advances in surgical rehabilitation in thyroid eye disease","volume":"18","author":"Goldberg","year":"2008","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ncl.2025.12.002_bib53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/WCO.0000000000000894","article-title":"Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment","volume":"34","author":"Johnson","year":"2021","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2025.12.002_bib54","first-page":"3683","article-title":"Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and\/or orbital decompression surgery. Graefe\u2019s Archive for","volume":"260","author":"Rezar-Dreindl","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.ncl.2025.12.002_bib55","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:21:02Z","timestamp":1776802862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0733861925000921"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.12.002","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on Treatment in Thyroid Eye Disease for the Neurologist","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}